Swiss biotech Oculis has raised $21 million in a Series B round backed by investors including Novartis (NYSE:NVS) and Bay City Capital. The company is developing topical drugs for back-of-the-eye diseases, which are normally treated with painful injections directly into the eye. Oculis reported that its newly-acquired funds will be used to support the clinical development of […]
Novartis
Pear Therapeutics raises $50m for digital substance use disorder therapies
Pear Therapeutics said today that it closed a $50 million Series B round to help commercialize its prescription digital substance abuse therapies. Temasek led the round and was joined by 5AM Ventures, Jazz Venture Partners, Novartis (NYSE:NVS) and others. In September, the company’s reSET therapy became the first prescription digital therapeutic approved by the FDA. One […]
Mass Innovation Labs expands to give startups a better way to do research
At the 124,000-square foot Cambridge headquarters of Mass Innovation Labs, co-founder & CEO Amrit Chaudhuri points to a cluster of tables and identifies them one by one: This startup went public and did a massive deal with Merck (NYSE:MRK), he says, and sits shoulder-to-shoulder with a different company working on a Phase II clinical asset. More than a […]
Lung cancer expert: Smoking stigma still hurting patients, families and research
A number of therapies designed to treat patients with lung cancer have been approved this year, including products from Novartis (NYSE:NVS), Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY). That progress is exciting for Dr. Fred Hirsch, the head of the International Association for the Study of Lung Cancer. “We do have a lot of good things to tell the […]
Semma Therapeutics closes $114m round to advance cell therapy for Type I diabetes
Semma Therapeutics has closed an oversubscribed $114 million Series B round to help fund the development of its encapsulated stem cell-derived islet therapy for Type I diabetes. The Cambridge, Mass.-based company reported that it plans to use the newly-acquired funds to bring its cell therapy through clinical proof-of-concept studies, as well as explore other regenerative […]
Earnings round-up: Biogen, Lilly & Novartis post Street-beating Q3 results
When Johnson & Johnson posted its third quarter financial results last week, the healthcare giant credited its revenue growth to the strength of its pharmaceutical business. Three more pharmaceutical companies posted their Q3 results today, topping revenue and earnings estimates from analysts. Here’s a round-up of Q3 earnings from Biogen (NSDQ:BIIB), Eli Lilly (NYSE:LLY) and Novartis (NYSE:NVS). Biogen […]
This company helps cell therapies travel around the world
With Gilead Sciences (NSDQ:GILD) and Novartis (NYSE:NVS) leading the way, cell therapies are moving on to the market and into the clinics for patients that have no other option. Companies making CAR-T therapies use a patient’s own cells to genetically engineer a cancer-killing cellular therapy that is then delivered back to the patient. And one 55-person company […]
Kite wins FDA approval for first adult CAR-T cell therapy
More than a month before it was due to make a decision, the FDA yesterday approved a CAR-T cell therapy from Kite Pharma (NSDQ:KITE) – the first of its kind for adults. The therapy, which is made from a patient’s own cells, is designed to treat adults with non-Hodgkin lymphoma who have failed at least two […]
10 of the world’s largest medical device companies
When it comes to the largest medical device companies, it’s a changing cast of players – as demonstrated once again in Medical Design & Outsourcing’s latest Big 100 list. We pulled financial regulatory filings and reached out major companies to create a list of the 100 largest medical device companies in the world, ranked by […]
Oral drug delivery startup raises $39m for robotic pill
San Jose, Calif.-based Rani Therapeutics has some seriously big-name backers: Alphabet (NSDQ:GOOGL), Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN) have all invested in the startup. This month, the company raised $38.7 million as part of a $126.5 million offering of equity and options or warrants, according to an SEC filing. So far, 12 investors have contributed to the offering. Rani […]
